Anzeige
Meldung des Tages: 0,01 % von 1 BILLIONEN USD = 100 MILLIONEN USD — Und UberDoc ist gerade erst an die Börse gegangen

Sandoz Group News

Aktie
WKN:  A3ETYB ISIN:  CH1243598427 US-Symbol:  SDZXF Branche:  Pharmazeutika Land:  Schweiz
71,97 €
+1,17 €
+1,65%
10.04.26
Depot/Watchlist
Marktkapitalisierung *
27,76 Mrd. €
Streubesitz
46,54%
KGV
-
Dividende
0,65 EUR
Dividendenrendite
1,05%
Nachhaltigkeits-Score
60 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,07: MM97VX
Werbung

Sandoz Group News

09.04.26 - EQS
Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG
Sandoz Group AG / Key word(s): AGMEGM Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG 09.04.2026 / ...
18.03.26 - EQS
Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets
Sandoz Group AG / Key word(s): Agreement Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up ...
11.03.26 - EQS
Sandoz issues CHF 550 million in bonds and extends its USD  2 billion revolving credit facility by one year
Sandoz Group AG / Key word(s): Bond Sandoz issues CHF 550 million in bonds and extends its USD  2 billion revolving credit facility by one year 11.03.2026 / 07:00 CET/CEST
10.03.26 - EQS
Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth
Sandoz Group AG / Key word(s): Strategic Company Decision/Personnel Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry ...
25.02.26 - EQS
Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
Sandoz Group AG / Key word(s): Annual Results Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth 25-Feb-2026 / 07:00 ...
23.02.26 - EQS
Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
Sandoz Group AG / Key word(s): Regulatory Approval Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars ...
18.02.26 - EQS
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
Sandoz Group AG / Key word(s): Regulatory Approval Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-​abzv) label for multiple retinal indications 18.02.2026 / ...
14.01.26 - EQS
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
Sandoz Group AG / Key word(s): Regulatory Approval Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership ...
12.01.26 - EQS
Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity
Sandoz Group AG / Key word(s): Conference Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden ...
08.12.25 - EQS
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
Sandoz Group AG / Key word(s): Acquisition Sandoz completes strategic acquisition of Just-​Evotec Biologics EU SAS, asserting biosimilars leadership 08.12.2025 / 07:00 CET/CEST
01.12.25 - EQS
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz Group AG / Key word(s): Market Launch Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-​related bone disease and ...
24.11.25 - EQS
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz Group AG / Key word(s): Market Launch Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases 24-Nov-2025 ...
17.11.25 - EQS
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz Group AG / Key word(s): Market Launch Sandoz launches TYRUKO® (natalizumab-​sztn) in US, as first and only multiple sclerosis biosimilar 17-Nov-2025 / 07:00 CET/CEST ...
12.11.25 - EQS
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz Group AG / Key word(s): Agreement Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab 12.11.2025 / 07:35 CET/CEST
04.11.25 - EQS
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz Group AG / Key word(s): Agreement Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-​Evotec Biologics EU SAS in Toulouse 04.11.2025 ...
30.10.25 - EQS
Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
Sandoz Group AG / Key word(s): Sales Result/9 Month figures Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded 30-Oct-2025 / 07:00 ...
09.09.25 - EQS
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sandoz Group AG / Key word(s): Agreement Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar 09-Sep-2025 / 07:00 ...
28.08.25 wallstreetONLINE Redaktion
Neustart an der Börse: Milliardenwert in Gefahr: Schafft dieser Pharmakonzern den IPO trotz Schulden?
Nach dem geplatzten Frühstart setzt Stada erneut auf ein IPO. Anleger müssen entscheiden, ob sie trotz Milliardenverschuldung an das Börsen-​Comeback glauben.Der hessische ...
28.08.25 - EQS
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options
Sandoz Group AG / Key word(s): Product Launch Sandoz launches rivaroxaban in Germany, expanding access to high-​quality antithrombotic treatment options 28.08.2025 / 07:00 ...
12.08.25 - GlobeNewswire
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
MEDIA RELEASE

Newssuche

Videos

newspaper
07.04.26 -4,86%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »